TCEAL7

Across TCGA pan-cancer cohorts, TCEAL7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCEAL7 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TCEAL7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCEAL7 expression acts as an unfavorable survival marker.

HNSC, LUAD, and LIHC are the cancer types where TCEAL7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.170	0.696	.010	18	view →
LUAD	OS	Median	All	0.258	0.812	.004	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCEAL7–HNSC (DFS)

Open the HNSC breakdown →